The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a

Pneumonitis (ILD), acute and/or severe (may produce the ARDS pattern)

Publications

Castro M, Veeder MH, Mailliard JA, Tazelaar HD, Jett JR

A prospective study of pulmonary function in patients receiving mitomycin.

Chest. 1996;109(4):939-44

Buzdar AU, Legha SS, Luna MA, Tashima CK, Hortobagyi GN, Blumenschein GR

Pulmonary toxicity of mitomycin.

Cancer. 1980;45(2):236-44

Luedke D, McLaughlin TT, Daughaday C, Luedke S, Harrison B, Reed G, Martello O

Mitomycin C and vindesine associated pulmonary toxicity with variable clinical expression.

Cancer. 1985;55(3):542-5

Chang AY, Kuebler JP, Pandya KJ, Israel RH, Marshall BC, Tormey DC

Pulmonary toxicity induced by mitomycin C is highly responsive to glucocorticoids.

Cancer. 1986;57(12):2285-90